Prescribing recommendations for interferon-beta in multiple sclerosis

CNS Drugs

Volumn 8, Issue 2, 1997, Pages 102-112

  Weinstock Guttman, Bianca ^a   Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CYSTEINE; INTERFERON BETA SERINE; PLACEBO; SERINE; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SUBSTITUTION; AUTOIMMUNITY; BREAST FEEDING; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG THERAPY; ESCHERICHIA COLI; ETIOLOGY; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MAMMAL CELL; META ANALYSIS; MONITORING; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REHABILITATION; RELAPSE; REVIEW;

EID: 0030745098     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708020-00002     Document Type: Review

References (41)

1. Raine C. The Dale E McFarlin Memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36 Suppl.: S61-72
2. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 1: clinical course and disability. Brain 1989; 112: 113-46
3. Lublin F, Reingold S, NMSS Advisory Committee on Clinical Trials of New Agents In Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11
4. Salmi A, Reunanen M, Ilonen J, et al. Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin Exp Immunol 1983; 52: 241-9
5. Sibley W, Bamford C, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 2: 1313-5
6. Andersen O, Lygner PE, Bergstrom T, et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurology 1993; 240: 417-22
7. Jacobs L, O'Malley J, Freeman A, et al. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214: 1026-8
8. Huber M, Bamborschke S, Assheuer J, et al. Intravenous natural beta Interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurology 1988; 235: 171-3
9. Flenniken A, Galabru J, Rutherford M, et al. Expression of interferon-induced genes in different tissues of mice. J Virol 1988; 62: 3077-83
10. Wong GH, Bartlett PF, Clark-Lewis I, et al. Inducible expression of H2 and la antigens on brain cells. Nature 1984; 310: 688-91
11. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
12. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis of results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983; 13: 227-31
14. Stone A, Frank J, Albert P, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-9
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 1996; 39: 285-94
16. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85
17. Weissmann C, Weber H. The Interferon genes. Prog Nucleic Acid Res Mol Biol 1986; 33: 251-300
18. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biologic effect, mechanisms of action, and use in multiple sclerosis, Ann Neurol 1995; 37: 7-15
19. Panitch H, Hirsch R, Schindler J, et al. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-102
20. Beck J, Rondot P, Calinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations.' Acta Neurol Scand 1991; 78: 318-23
21. Panitch H, Hinsch RL, Schindler J, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-5
22. Ransohoff RM, Devajyothi C, Estes ML, et al. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol 1991; 33: 103-12
23. Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferonbeta on the interferon-gamma-induced expression of la antigen in murine macrophages. J Immunol 1985; 135: 1857-63
24. Mehindate K, al-Daccak R, Schall TJ, et al. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes: differential regulation by interleukin-4 and dexamethasone. J Biol Chem 1994; 269: 32063-9
25. Lu H-T, Railey JL, Babcock GT, et al. IFN beta acts downstream of CIITA mRNA accumulation to block MHC class II gene expression in IFN-γ-treated cells and requires the 48-kDa DNA-bindmg protein (ISGF3-g). J Exp Med 1995; 182 (5): 1517-25
26. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-27
27. Rudick RA, Ransohoff R, Medendorp S, et al. IFN beta-1a (Avonex) increuses CSF interleukin 10 in patients with relapsing multiple sclerosis [abstract]. Ann Neurol 1996; 40: 553
28. Yu M, Nishiyama A, Trapp BD, et al. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64: 91-100
29. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996; 183: 1777-88
30. Report of Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994; 44: 1537-40
31. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-66
32. Thompson A, Kermode A, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62
33. Dayal AS, Jensen MA, Lledo A, et al. Interferon-gamma-sccreting cells in multiple sclerosis patients treated with Interferon beta-1b. Neurology 1995; 45: 2173-7
34. Rieckmann P, Weber F, Gunther A, et al. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon beta-1b treatment in patients with multiple sclerosis [letter]. Neurology 1996; 47: 604
35. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996; 47: 123-9
36. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting MS: results of a phase III multicenter, double blind placebo-controlled trial. Neurology 1995; 45: 1268-76
37. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI analysis group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94
38. Paty DW, Goodkin D, Thompson A, et al. Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies. Neurology 1996; 47: 865-6
39. Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch Phys Med Rehabil 1993; 74: 26-31
40. Catanzaro M, Weinert C. Economic status of families living with multiple sclerosis. Int J Rehabil Res 1992; 15: 209-18
41. Walley T, Barton S. A purchaser perspective of managing new drugs: Interferon beta as a case study. BMJ 1995; 311: 796-9